Patient Global Impression of Change much or very much improved · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in much or very much improved on PGIC during longest compared with placebo (low certainty).
1 finding from 1 review
PGIC very much improved · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in very much improved on PGIC during longest compared with placebo (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in withdrawals due to adverse events during longest compared with placebo (low certainty).
1 finding from 1 review
Number of participants reporting an adverse event · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in participants experiencing at least 1adverse event during longest compared with placebo (low certainty).
1 finding from 1 review
Lack of efficacy withdrawal · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in withdrawal due to lack of efficacy (12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · adults with painful diabetic neuropathy
Topical clonidine (TC) showed no clear difference in participant‐reported pain relief of 50% or greater during longest compared with active comparator (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 30% or greater · adults with painful diabetic neuropathy
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Participants with ≥ 1 vomiting episode · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in vomiting (≥1 episode) compared with placebo (low certainty).
1 finding from 1 review
Nausea · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in nausea (≥1 episode) compared with placebo (low certainty).
1 finding from 1 review
Adverse events · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Number of vomiting episodes · adults receiving intravenous opioids
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Nausea severity · adults receiving intravenous opioids
1 finding from 1 review
Use of rescue medication · adults receiving intravenous opioids
Prophylactic dopamine antagonist antiemetic medications showed no clear difference in rescue medication compared with placebo (low certainty).
1 finding from 1 review
Lean body mass · cancer cachexia in adults
1 finding from 1 review
Occurrence of adverse events · cancer cachexia in adults
It is very uncertain whether multimodal intervention (exercise plus other interventions) plus… changes occurrence of adverse events compared with usual care (very low certainty).
1 finding from 1 review
Muscle endurance/strength outcomes · cancer cachexia in adults
1 finding from 1 review
Maximal and submaximal exercise capacity** Submaximal capacity · cancer cachexia in adults
1 finding from 1 review
Fatigue · cancer cachexia in adults
1 finding from 1 review
Health‐related quality of life · cancer cachexia in adults
1 finding from 1 review
Adherence to prescribed exercise programmes · cancer cachexia in adults
It is very uncertain whether exercise plus usual care changes adherence to prescribed exercise programmes compared with usual care (very low certainty).
1 finding from 1 review